PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter revenue at the high end of its guidance range and earnings per share exceeding guidance. Executive Summary Q2 2025 vs. Prior-year Quarter Revenue $386.1 million; (12.1)% 0.3% FX impact or $1.4 million Earnings Per Share (EPS) $0.43 compared to $(2.38) or $0.21 excluding impairment and other charges Customers 771,407; (14)% Paid Affiliates 130,799; (16)% Sales Leaders 29,593; (23)% “We are pleased w
Related Questions
What is the revenue mix (direct sales, subscriptions, etc.) and how did it shift year‑over‑year?
What was the exact revenue guidance range and where did the actual revenue fall within it?
What is the current cash position, free cash flow, and any plans for share repurchases or dividend changes?
How does the EPS of $0.43 compare to consensus analysts' expectations?
Has management updated guidance for Q3 and full‑year 2025 revenue and EPS?
What drove the EPS beat—cost reductions, higher gross margins, or one‑time items?
What key points does management plan to highlight in the upcoming earnings call?
What technical indicators and trading volume patterns are emerging after this release?
What were the impairment and other charges that led to the prior‑year loss, and are they recurring?
What are the implications of the decline in customers (-14%), paid affiliates (-16%), and sales leaders (-23%) for future growth?
How did the $1.4 M FX impact affect the top line, and what currency exposure remains?
How does Nu Skin's performance compare to peers such as Amway, Herbalife, and other direct‑selling companies?
Are there any new product launches, market expansions, or regulatory developments mentioned?